Home » Stocks » MGEN

Miragen Therapeutics, Inc. (MGEN)

Jan 20, 2021 - Stock symbol was changed to VRDN
Stock Price: $23.01 USD 0.00 (0.00%)
Updated Jan 19, 2021 4:00 PM EST
Market Cap 89.93M
Revenue (ttm) 1.88M
Net Income (ttm) -30.09M
Shares Out 3.72M
EPS (ttm) -9.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Jan 19, 2021
Last Price $23.01
Previous Close $23.01
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 22.92 - 23.90
Day's Volume 0
52-Week Range 5.45 - 30.60

News

Hide News
GlobeNewsWire - 5 days ago

BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics...

Other stocks mentioned: VRDN
GlobeNewsWire - 1 month ago

Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor's Xtend™ half-life extension technology

Seeking Alpha - 1 month ago

Miragen has had years of disappointing share price performance with a cumulative loss of more than 90%. This is a reflection of the poor results in the two drug candidates that until recently ...

GlobeNewsWire - 2 months ago

BOULDER, Colo., Nov. 10, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a biotechnology company advancing new treatments for patients with diseases that are underserved by...

InvestorPlace - 2 months ago

It was thrilling to watch MGEN stock spike, and the bull move might not be over as Miragen's new acquisition puts high-need medicine in focus. The post Value-Added Acquisition Clears the Runwa...

InvestorPlace - 2 months ago

Miragen Therapeutics news of its acquisition of Viridian Therapeutics has MGEN stock skyrocketing on Wednesday. The post Miragen Therapeutics News: Why MGEN Stock Is Skyrocketing Today appeare...

GlobeNewsWire - 2 months ago

Acquisition includes clinical stage anti-IGF - 1R monoclonal antibody, VRDN-001 , intended for the treatment of thyroid eye disease (TED)

GlobeNewsWire - 3 months ago

miRagen decides to discontinue further internal development of cobomarsen miRagen decides to discontinue further internal development of cobomarsen

GlobeNewsWire - 4 months ago

Lee Rauch appointed President and CEO, following resignation by William Marshall

GlobeNewsWire - 5 months ago

BOULDER, Colo., Aug. 20, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietar...

Seeking Alpha - 5 months ago

miRagen Therapeutics' (MGEN) CEO Bill Marshall on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of 29.41% and -74.23%, respectively, for the quarter ended June 2020.

GlobeNewsWire - 5 months ago

BOULDER, Colo., Aug. 05, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietar...

GlobeNewsWire - 5 months ago

BOULDER, Colo., Aug. 04, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-target...

Zacks Investment Research - 5 months ago

Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 6 months ago

BOULDER, Colo., July 23, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-target...

GlobeNewsWire - 6 months ago

BOULDER, Colo., July 22, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-target...

GlobeNewsWire - 6 months ago

BOULDER, Colo., July 02, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-target...

Forbes - 6 months ago

If you’re looking to hedge against a coming pullback in the markets, we've used our deep learning algorithms and AI to identify the Top Shorts today.

Other stocks mentioned: AGEN, ATOM, AXLA, EYPT
GlobeNewsWire - 7 months ago

Key Opinion Leader call on IPF scheduled for 11 a.m. ET on Tuesday, June 23rd Key Opinion Leader call on IPF scheduled for 11 a.m. ET on Tuesday, June 23rd

GlobeNewsWire - 7 months ago

BOULDER, Colo., June 18, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-target...

GlobeNewsWire - 7 months ago

miRagen to announce encouraging new preclinical safety and efficacy data for MRG-229 in IPF on June 22nd; and provide an update on the development program during the KOL call miRagen to announ...

Seeking Alpha - 8 months ago

Miragen Therapeutics, Inc. (MGEN) CEO Bill Marshall on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Seeking Alpha - 10 months ago

miRagen Therapeutics, Inc. (MGEN) CEO Bill Marshall on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of -24.00% and -9.56%, respectively, for the quarter ended December 2019.

Zacks Investment Research - 11 months ago

Is (MGEN) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 11 months ago

BOULDER, Colo., Feb. 07, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-target...

GlobeNewsWire - 11 months ago

BOULDER, Colo., Feb. 06, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-target...

GlobeNewsWire - 11 months ago

Cobomarsen-treated adult T-cell leukemia/lymphoma (ATLL) patients with residual disease had a median survival time (MST) of 26 months compared with 7.4 months in a historical cohort - - -

GlobeNewsWire - 1 year ago

BOULDER, Colo., Dec. 11, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a ...

Seeking Alpha - 1 year ago

miRagen Therapeutics' (MGEN) CEO Bill Marshall on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of -20.00% and -58.38%, respectively, for the quarter ended September 2019.

Zacks Investment Research - 1 year ago

Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 1 year ago

BOULDER, Colo., Oct. 28, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a s...

GlobeNewsWire - 1 year ago

Data included in an oral presentation at the 15th annual meeting of the Oligonucleotide Therapeutics Society

Seeking Alpha - 1 year ago

miRagen Therapeutics' (MGEN) CEO Bill Marshall on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of 21.62% and 184.07%, respectively, for the quarter ended June 2019.

Zacks Investment Research - 1 year ago

Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Seeking Alpha - 1 year ago

miRagen Therapeutics, Inc. (MGEN) CEO Bill Marshall on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of -8.57% and -72.44%, respectively, for the quarter ended March 2019.

Zacks Investment Research - 1 year ago

Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Seeking Alpha - 1 year ago

miRagen Therapeutics, Inc. (MGEN) CEO William Marshall on Q4 2018 Results - Earnings Call Transcript

About MGEN

Miragen Therapeutics, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found ... [Read more...]

Industry
Biotechnology
Founded
2006
CEO
William Marshall
Employees
45
Stock Exchange
NASDAQ
Ticker Symbol
MGEN
Full Company Profile

Financial Performance

In 2019, MGEN's revenue was $4.46 million, a decrease of -46.80% compared to the previous year's $8.39 million. Losses were -$41.87 million, 28.0% more than in 2018.

Financial Statements